



175

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: FORSSMANN et al.

Serial No.: 10/760,557

Group Art Unit: 1653

Filed: January 21, 2004

For: HUMAN CIRCULATING CYTOKINE CC-1

**REQUEST FOR FILING RECEIPT CORRECTION**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1405

Sir:


Please correct the original filing receipt, copy attached, for the above-identified application as follows:

In the "Foreign Applications" section, please change the date of the second application from "03/08/1994" to --08/03/1994--.


Kindly return the "Corrected" filing receipt to the undersigned attorneys of record.

Respectfully submitted,

JACOBSON HOLMAN PLLC

By:   
William E. Player  
Reg. No. 31,409

400 Seventh Street, N.W.  
Washington, D.C. 20004-2201  
(202) 638-6666  
Atty. Docket: P60448US1  
Date: September 6, 2005  
WEP:crj



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/760,557	01/21/2004	1653	450	P60448US1	5	11	3

CONFIRMATION NO. 8650

## UPDATED FILING RECEIPT



\*OC000000015143859\*

00136

JACOBSON HOLMAN PLLC  
 400 SEVENTH STREET N.W.  
 SUITE 600  
 WASHINGTON, DC 20004

Date Mailed: 02/10/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Wolf-Georg Forssmann, Hannover, GERMANY;  
 Peter Schulz-Knappe, Hannover, GERMANY;  
 Markus Meyer, Hannover, GERMANY;  
 Hans-Jurgen Magert, Hannover, GERMANY;

## Assignment For Published Patent Application

Wolf-Georg FORSSMANN

## Power of Attorney:

Irwin Aisenberg-19007  
 Marvin Stern-20640  
 Harvey Jacobson Jr-20851  
 John Holman-22769  
 D Price-24514

Michael Slobasky-26421  
 Jonathan Scherer-29851  
 William Player-31409

## Domestic Priority data as claimed by applicant

This application is a CON of 08/666,340 08/18/1998 ABN  
 which is a 371 of PCT/EP94/04282 12/22/1994

## Foreign Applications

GERMANY DE 43 44 397.4 12/24/1993  
 GERMANY DE 44 27 395.9 03/08/1994

If Required, Foreign Filing License Granted: 05/04/2004

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/760,557**

Projected Publication Date: 05/19/2005

Non-Publication Request: No

Early Publication Request: No

**\*\* SMALL ENTITY \*\***

**Title**

Human circulating cytokine CC-1

**Preliminary Class**

435

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations, especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).